CORRELATION OF SERUM URIC ACID WITH LIPID PROFILE AND GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS

Authors

  • AMIT SINGH Department of Biochemistry, Nalanda Medical College, Patna, Bihar, India
  • RAMAN RAHI Department of Biochemistry, Nalanda Medical College, Patna, Bihar, India
  • CHANDAN KUMAR Department of Biochemistry, Nalanda Medical College, Patna, Bihar, India
  • PRABHAT KUMAR SINGH Department of Biochemistry, Nalanda Medical College, Patna, Bihar, India
  • SANTOSH KUMAR Department of Biochemistry, Nalanda Medical College, Patna, Bihar, India

DOI:

https://doi.org/10.22159/ijcpr.2026v18i1.8042

Keywords:

T2DM, Uric acid, Glycemic control, HDL-c, TG, LDL-c

Abstract

Objective: Type 2 diabetes mellitus (T2DM) is often associated with metabolic abnormalities, including dyslipidemia and hyperuricemia. Recent studies suggest that elevated serum uric acid (SUA) levels may correlate with poor glycemic control and adverse lipid profiles. This study aimed to evaluate the relationship between SUA, lipid parameters, and glycemic markers among T2DM patients.

Methods: A cross-sectional study was conducted on 150 patients with T2DM. Fasting blood samples were analyzed for serum uric acid, fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), and lipid profile, including total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL). Pearson correlation was used to assess relationships between SUA and biochemical variables.

Results: mean SUA was 6.2±1.1 mg/dl. SUA showed a positive correlation with triglycerides (r = 0.39, p<0.001) and LDL (r = 0.29, p = 0.002), and a negative correlation with HDL (r = –0.28, p = 0.004). A weak positive correlation was observed between SUA and HbA1c (r = 0.16, p = 0.05). Patients with poor glycemic control (HbA1c>7%) had higher SUA levels compared to those with good control.

Conclusion: Elevated serum uric acid levels are associated with dyslipidemia and poor glycemic control in T2DM patients. Routine monitoring of SUA may provide additional insight into metabolic risk and cardiovascular complications.

Downloads

Download data is not yet available.

References

1. American Diabetes Association Professional Practice Committee. Introduction and methodology: standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S1-4. doi: 10.2337/dc24-SINT, PMID 38078587.

2. International Diabetes Federation. IDF diabetes atlas. 10th ed. Brussels, Belgium: IDF; 2024.

3. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28(4):629-36. doi: 10.1161/ATVBAHA.107.151092, PMID 18174459.

4. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003;46(6):733-49. doi: 10.1007/s00125-003-1111-y, PMID 12774165.

5. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811-21. doi: 10.1056/NEJMra0800885, PMID 18946066.

6. Li C, Hsieh MC, Chang SJ. Metabolic syndrome diabetes and hyperuricemia. Curr Opin Rheumatol. 2013;25(2):210-6. doi: 10.1097/BOR.0b013e32835d951e, PMID 23370374.

7. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120(5):442-7. doi: 10.1016/j.amjmed.2006.06.040, PMID 17466656.

8. Grayson PC, Kim SY, La Valley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63(1):102-10. doi: 10.1002/acr.20344, PMID 20824805.

9. Sautin YY, Johnson RJ. Uric acid: the oxidant–antioxidant paradox. Nucleosides, Nucleotides Nucleic Acids. 2008;27(6):608-19. doi: 10.1080/15257770802138558, PMID 18600514.

10. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2006;290(3):F625-31. doi: 10.1152/ajprenal.00140.2005, PMID 16234313.

11. Chen L, Yu S, Zhu Y, Zhang X, Luo Y, Wang L. Association between serum uric acid and metabolic syndrome: a meta-analysis. Clin Nutr. 2019;38(1):193-9. doi: 10.1016/j.clnu.2018.01.027.

12. Tsouli SG, Karagiannis A, Zachariadou T, Chrysostomou E, Liakos A, Papadakis J. The role of uric acid in cardiovascular risk. Curr Med Res Opin. 2006;22(12):235-42. doi: 10.1185/030079906X124327.

13. Johnson RJ, Nakagawa T, Sanchez Lozada LG, Shafiu M, Sundaram S, Le M. Sugar uric acid and the etiology of diabetes and obesity. Diabetes. 2013;62(10):3307-15. doi: 10.2337/db12-1814, PMID 24065788.

14. Xiong Q, Liu J, Xu Y. Effects of uric acid on diabetes mellitus and its chronic complications. Int J Endocrinol. 2019;2019:9691345. doi: 10.1155/2019/9691345, PMID 31737070.

15. LV Q, Meng XF, He FF, Chen S, Su H, Xiong J. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PLOS One. 2013;8(2):e56864. doi: 10.1371/journal.pone.0056864, PMID 23437258.

16. Kumar S, Mondal H, Lata M, Behera JK, Priyadarshini B. Correlation of serum uric acid with lipid profile in patients with type 2 diabetes mellitus. J Clin Diagn Res. 2022;16(4):BC05-9. doi: 10.4103/jfmpc.jfmpc_2131_21.

17. Kumar S, Sharma R, Gupta A, Verma P. Serum uric acid: a potential marker of metabolic syndrome in type 2 diabetes. J Assoc Physicians India. 2018;66(11):30-4.

18. Uric acid as an emerging biomarker in metabolic and cardiovascular diseases in South Asians. Indian Heart J. 2020;72(3):185-90. doi: 10.1016/j.ihj.2019.11.200.

Published

15-01-2026

How to Cite

SINGH, AMIT, et al. “CORRELATION OF SERUM URIC ACID WITH LIPID PROFILE AND GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS”. International Journal of Current Pharmaceutical Research, vol. 18, no. 1, Jan. 2026, pp. 93-96, doi:10.22159/ijcpr.2026v18i1.8042.

Issue

Vol 18, Issue 1 (Jan-Feb), 2026

Section

Original Article(s)
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.